How much does Tafinlar (Dabrafenib Mesylate Capsules) Cost& price without insurance in China?
Tafinlar® is the commercial brand name of Dabrafenib Mesylate Capsules, a selective BRAF kinase inhibitor developed by Novartis. It exerts anti-tumor activity by specifically inhibiting the mutated BRAF protein (BRAF V600E/V600K), thereby blocking the aberrant activation of the MAPK signaling pathway and suppressing tumor cell proliferation.
Main Indications
As a single agent or in combination with trametinib, for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation-positive;
In combination with trametinib, for the treatment of metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation-positive.
Common Side Effects
Common adverse reactions: Fever, chills, fatigue, rash, headache, nausea, diarrhea, vomiting, arthralgia, myalgia, and alopecia.
Laboratory abnormalities: Decreased white blood cell count, decreased lymphocyte count, anemia, hypophosphatemia, and increased blood glucose levels.
Severe but manageable risks: New primary malignancies (including cutaneous squamous cell carcinoma), hyperthermia, serious skin reactions, ocular toxicities (uveitis, iritis), and cardiomyopathy.
Approval Status in China
Tafinlar® (Dabrafenib Mesylate Capsules, 75mg) was officially approved for marketing in China in April 2019. It is currently a prescription drug included in China’s Category B medical insurance.
Buy Tafinlar (Dabrafenib Mesylate Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
